Market revenue in 2023 | USD 158.8 million |
Market revenue in 2030 | USD 419.0 million |
Growth rate | 14.9% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.89% in 2023. Horizon Databook has segmented the India immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Biomarkers are important research and clinical tools in the diagnosis & treatment of the progression, recurrence, & severity of neurological diseases, as well as for the R&D of novel immunoassay kits. Several research and academic institutes in the country are working to discover novel biomarkers that offer proper diagnosis & treatment of diseases.
Key market players in India are focusing on the development and commercialization of novel biomarkers to address the unmet needs of patients in neurodegenerative disease areas. In March 2020, the Central Drugs Standard Control Organization (CDSCO) published several notices to safeguard the supply of critical IVDs used in the detection of diseases.
Manufacturers with approved IVD kits in other markets are encouraged to fast-track approval from the Drugs Controller General of India (DCGi). This movement from the agency can slow down the approval of other IVD kits, including immunoassays, thereby restraining market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the India immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into India immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account